Alaunos Operating Income vs Net Income Analysis
TCRT Stock | USD 1.09 0.04 3.81% |
Alaunos Therapeutics financial indicator trend analysis is way more than just evaluating Alaunos Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alaunos Therapeutics is a good investment. Please check the relationship between Alaunos Therapeutics Operating Income and its Net Income accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Alaunos Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Alaunos Stock please use our How to Invest in Alaunos Therapeutics guide.
Operating Income vs Net Income
Operating Income vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alaunos Therapeutics Operating Income account and Net Income. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Alaunos Therapeutics' Operating Income and Net Income is 0.5. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Net Income in the same time period over historical financial statements of Alaunos Therapeutics, assuming nothing else is changed. The correlation between historical values of Alaunos Therapeutics' Operating Income and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Alaunos Therapeutics are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Operating Income i.e., Alaunos Therapeutics' Operating Income and Net Income go up and down completely randomly.
Correlation Coefficient | 0.5 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Operating Income
Operating Income is the amount of profit realized from Alaunos Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Alaunos Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Alaunos Therapeutics financial statement analysis. It represents the amount of money remaining after all of Alaunos Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from Alaunos Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alaunos Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Alaunos Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Alaunos Stock please use our How to Invest in Alaunos Therapeutics guide.At this time, Alaunos Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 24.6 M in 2024, whereas Enterprise Value is likely to drop slightly above 10.3 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Cost Of Revenue | 740K | 2.8M | 2.3M | 1.7M | Reconciled Depreciation | 2.6M | 2.8M | 2.8M | 1.9M |
Alaunos Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Alaunos Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Alaunos Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 109.1M | 146.3M | 94.9M | 64.9M | 8.3M | 7.8M | |
Total Stockholder Equity | 95.0M | 124.0M | 58.1M | 38.6M | 6.3M | 6.0M | |
Net Debt | (77.4M) | (110.3M) | (46.7M) | (19.5M) | (6.1M) | (6.4M) | |
Retained Earnings | (684.1M) | (764.1M) | (842.9M) | (880.6M) | (915.8M) | (870.0M) | |
Cash | 79.7M | 115.1M | 76.1M | 39.1M | 6.1M | 5.8M | |
Non Current Assets Total | 3.6M | 15.8M | 16.0M | 11.1M | 2K | 1.9K | |
Non Currrent Assets Other | 9.7M | 240K | 875K | 673K | 542K | 0.0 | |
Other Assets | 240K | 875K | 673K | 542K | 1.0 | 0.95 | |
Cash And Short Term Investments | 79.7M | 115.1M | 76.1M | 39.1M | 6.1M | 5.8M | |
Net Receivables | 3.3M | 4.7M | 1.1M | 4K | 1K | 950.0 | |
Common Stock Shares Outstanding | 11.2M | 14.0M | 14.3M | 14.5M | 16.0M | 15.2M | |
Liabilities And Stockholders Equity | 109.1M | 146.3M | 94.9M | 64.9M | 8.3M | 7.8M | |
Non Current Liabilities Total | 4K | 1.6M | 4.0M | 20.8M | 2.2M | 0.0 | |
Other Stockholder Equity | 779.0M | 887.9M | 900.7M | 918.9M | 922.1M | 968.2M | |
Total Liab | 109.1M | 22.4M | 36.8M | 26.4M | 2.0M | 1.9M | |
Total Current Assets | 105.5M | 130.6M | 78.8M | 53.8M | 8.3M | 7.8M | |
Other Current Liab | 10.8M | 16.6M | 6.1M | 5.5M | 1.3M | 1.3M | |
Total Current Liabilities | 12.5M | 18.4M | 16.0M | 24.2M | 2.0M | 1.9M | |
Accounts Payable | 906K | 960K | 1.4M | 1.4M | 616K | 585.2K | |
Common Stock | 182K | 215K | 216K | 240K | 16K | 15.2K | |
Property Plant And Equipment Net | 3.4M | 14.9M | 15.4M | 10.6M | 2K | 1.9K | |
Other Current Assets | 22.4M | 10.9M | 1.7M | 799K | 2.2M | 2.1M | |
Net Tangible Assets | 95.0M | 124.0M | 58.1M | 38.6M | 44.3M | 55.8M | |
Property Plant Equipment | 3.4M | 14.9M | 15.4M | 8.5M | 9.7M | 8.1M | |
Net Invested Capital | 95.0M | 124.0M | 82.2M | 55.3M | 6.3M | 6.0M | |
Capital Stock | 182K | 215K | 216K | 240K | 16K | 15.2K | |
Net Working Capital | 93.0M | 112.2M | 62.8M | 29.6M | 6.3M | 6.0M |
Pair Trading with Alaunos Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alaunos Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alaunos Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Alaunos Stock
0.85 | EQ | Equillium | PairCorr |
Moving against Alaunos Stock
0.53 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to Alaunos Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alaunos Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alaunos Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alaunos Therapeutics to buy it.
The correlation of Alaunos Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alaunos Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alaunos Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alaunos Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Alaunos Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Alaunos Stock please use our How to Invest in Alaunos Therapeutics guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Alaunos Stock analysis
When running Alaunos Therapeutics' price analysis, check to measure Alaunos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alaunos Therapeutics is operating at the current time. Most of Alaunos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alaunos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alaunos Therapeutics' price. Additionally, you may evaluate how the addition of Alaunos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
CEOs Directory Screen CEOs from public companies around the world | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Alaunos Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alaunos Therapeutics. If investors know Alaunos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alaunos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (32.48) | Quarterly Revenue Growth (0.91) | Return On Assets (0.49) | Return On Equity (1.57) |
The market value of Alaunos Therapeutics is measured differently than its book value, which is the value of Alaunos that is recorded on the company's balance sheet. Investors also form their own opinion of Alaunos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alaunos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alaunos Therapeutics' market value can be influenced by many factors that don't directly affect Alaunos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alaunos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alaunos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alaunos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.